FIELD: biotechnology.
SUBSTANCE: invention relates to immunology. Disclosed is a pharmaceutical composition containing a purified human monoclonal antibody which specifically binds to interleukin 1-alpha (IL-1α)) and contains an amino acid sequence of a light chain variable region containing complementarity determining regions (CDR) with SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, and the heavy chain variable region amino acid sequence containing CDR with SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8.
EFFECT: invention provides treating diseases (inflammation, immune responses, tumor metastasis and haematopoiesis) by activating interleukin 1-alpha by specific high-affinity binding of the purified human monoclonal antibody to said cytokine.
2 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTI-GARP-TGF-β-ANTIBODIES | 2018 |
|
RU2767784C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
